日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I Study of Sorafenib Combined with Gemcitabine and Carboplatin in Patients with Advanced Solid Tumors

索拉非尼联合吉西他滨和卡铂治疗晚期实体瘤患者的I期研究

Voogd, Daphne W M; Lucassen, Merel J J; van der Noll, Ruud; Zielhuis, Sybrand W J; Boss, David; Beijnen, Jos H; Rosing, Hilde; Tibben, Matthijs; Huitema, Alwin D R; Schellens, Jan H M; Steeghs, Neeltje

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD

在DPYD公司内外发现与严重氟嘧啶类药物相关毒性相关的新型种系遗传变异

Knikman, Jonathan E; Zhai, Qinglian; Lunenburg, Carin A T C; Henricks, Linda M; Böhringer, Stefan; van der Lee, Maaike; de Man, Femke M; Offer, Steven M; Shrestha, Shikshya; Creemers, Geert-Jan; Baars, Arnold; Dezentjé, Vincent O; Imholz, Alexander L T; Jeurissen, Frank J F; Portielje, Johanna E A; Jansen, Rob L H; Hamberg, Paul; Droogendijk, Helga J; Koopman, Miriam; Nieboer, Peter; van de Poel, Marlène H W; Mandigers, Caroline M P W; van Schaik, Ron H N; Gelderblom, Hans; Mathijssen, Ron H J; Schellens, Jan H M; Cats, Annemieke; Guchelaar, Henk-Jan; Swen, Jesse J

Dihydropyrimidine dehydrogenase gene variants for predicting grade 4-5 fluoropyrimidine-induced toxicity: FUSAFE individual patient data meta-analysis

二氢嘧啶脱氢酶基因变异预测4-5级氟嘧啶类药物引起的毒性:FUSAFE个体患者数据荟萃分析

Le Teuff, Gwénaël; Cozic, Nathalie; Boyer, Jean-Christophe; Boige, Valérie; Diasio, Robert B; Taieb, Julien; Meulendijks, Didier; Palles, Claire; Schwab, Matthias; Deenen, Maarten; Largiadèr, Carlo R; Marinaki, Anthony; Jennings, Barbara A; Wettergren, Yvonne; Di Paolo, Antonello; Gross, Eva; Budai, Barna; Ackland, Stephen P; van Kuilenburg, André B P; McLeod, Howard L; Milano, Gérard; Thomas, Fabienne; Loriot, Marie-Anne; Kerr, David; Schellens, Jan H M; Laurent-Puig, Pierre; Shi, Qian; Pignon, Jean-Pierre; Etienne-Grimaldi, Marie-Christine

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

达拉非尼联合曲美替尼治疗 BRAFV600E 突变的罕见癌症:2 期 ROAR 试验

Subbiah, Vivek; Kreitman, Robert J; Wainberg, Zev A; Gazzah, Anas; Lassen, Ulrik; Stein, Alexander; Wen, Patrick Y; Dietrich, Sascha; de Jonge, Maja J A; Blay, Jean-Yves; Italiano, Antoine; Yonemori, Kan; Cho, Daniel C; de Vos, Filip Y F L; Moreau, Philippe; Fernandez, Elena Elez; Schellens, Jan H M; Zielinski, Christoph C; Redhu, Suman; Boran, Aislyn; Passos, Vanessa Q; Ilankumaran, Palanichamy; Bang, Yung-Jue

First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

首次人体 I 期研究,评估 OX40 激动剂 GSK3174998 与或不与帕博利珠单抗联合治疗特定晚期实体瘤患者的疗效 (ENGAGE-1)

Postel-Vinay, Sophie; Lam, Vincent K; Ros, Willeke; Bauer, Todd M; Hansen, Aaron R; Cho, Daniel C; Stephen Hodi, F; Schellens, Jan H M; Litton, Jennifer K; Aspeslagh, Sandrine; Autio, Karen A; Opdam, Frans L; McKean, Meredith; Somaiah, Neeta; Champiat, Stephane; Altan, Mehmet; Spreafico, Anna; Rahma, Osama; Paul, Elaine M; Ahlers, Christoph M; Zhou, Helen; Struemper, Herbert; Gorman, Shelby A; Watmuff, Maura; Yablonski, Kaitlin M; Yanamandra, Niranjan; Chisamore, Michael J; Schmidt, Emmett V; Hoos, Axel; Marabelle, Aurelien; Weber, Jeffrey S; Heymach, John V

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

一项单臂 II 期研究,旨在评估纳米喜树碱 NLG207 与恩扎卢胺联合治疗恩扎卢胺治疗晚期转移性去势抵抗性前列腺癌的疗效。

Schmidt, Keith T; Karzai, Fatima; Bilusic, Marijo; Cordes, Lisa M; Chau, Cindy H; Peer, Cody J; Wroblewski, Susan; Huitema, Alwin D R; Schellens, Jan H M; Gulley, James L; Dahut, William L; Figg, William D; Madan, Ravi A

A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancer

一项针对晚期癌症患者的 I 期剂量递增研究,评估了两个周期卡铂-奥拉帕尼联合化疗后序贯奥拉帕尼单药治疗的效果。

Geenen, Jill J J; Dackus, Gwen M H E; Schouten, Philip C; Pluim, Dick; Marchetti, Serena; Sonke, Gabe S; Jóźwiak, Katarzyna; Huitema, Alwin D R; Beijnen, Jos H; Schellens, Jan H M; Linn, Sabine C

A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors

GSK2849330(一种抗HER3单克隆抗体)在HER3表达实体瘤中的I期首次人体研究

Gan, Hui K; Millward, Michael; Jalving, Mathilde; Garrido-Laguna, Ignacio; Lickliter, Jason D; Schellens, Jan H M; Lolkema, Martijn P; Van Herpen, Carla L M; Hug, Bruce; Tang, Lihua; O'Connor-Semmes, Robin; Gagnon, Robert; Ellis, Catherine; Ganji, Gopinath; Matheny, Christopher; Drilon, Alexander

BRAF-Mutant Transcriptional Subtypes Predict Outcome of Combined BRAF, MEK, and EGFR Blockade with Dabrafenib, Trametinib, and Panitumumab in Patients with Colorectal Cancer

BRAF突变转录亚型可预测结直肠癌患者接受达拉非尼、曲美替尼和帕尼单抗联合BRAF、MEK和EGFR阻断治疗的疗效

Middleton, Gary; Yang, Yiqun; Campbell, Catarina D; André, Thierry; Atreya, Chloe E; Schellens, Jan H M; Yoshino, Takayuki; Bendell, Johanna C; Hollebecque, Antoine; McRee, Autumn J; Siena, Salvatore; Gordon, Michael S; Tabernero, Josep; Yaeger, Rona; O'Dwyer, Peter J; De Vos, Filip; Van Cutsem, Eric; Millholland, John M; Brase, Jan C; Rangwala, Fatima; Gasal, Eduard; Corcoran, Ryan B

Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment

奥拉帕尼在晚期实体瘤合并轻度或中度肝功能损害患者中的药代动力学和安全性研究

Rolfo, Christian; Isambert, Nicolas; Italiano, Antoine; Molife, L Rhoda; Schellens, Jan H M; Blay, Jean-Yves; Decaens, Thomas; Kristeleit, Rebecca; Rosmorduc, Olivier; Demlova, Regina; Lee, Myung-Ah; Ravaud, Alain; Kopeckova, Katerina; Learoyd, Maria; Bannister, Wendy; Locker, Gershon; de Vos-Geelen, Judith